Skip to content

Effects of Sumac spray and Benzydamine Hydrochloride spray on prevention of radiation induced acute mucositis in head and neck cancer

Effects of Sumac spray and Benzydamine Hydrochloride spray on prevention of radiation induced acute mucositis in head and neck cancer

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20161024030467N2
Enrollment
44
Registered
2022-01-26
Start date
2022-02-04
Completion date
Unknown
Last updated
2022-02-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oral mucositis. Oral mucositis (ulcerative)

Interventions

Intervention 1: Intervention group: Intervention group 1: Mucutin spray group who use the spray 4-8 times per day from a day before the start of radiotherapy up to two weeks of end of radiotherapy or

Sponsors

Shahid Beheshti University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Head and neck cancer patient Candidate for radiation therapy At least 2 regions of the studied areas in terms of mucositis (based on the mucositis scale) be in the field of radiation therapy Good performance status with ECOG questionnaire between 18 to 80 Willingness to participate in the study Physical and mental ability to cooperate in filling in the questionnaire

Exclusion criteria

Exclusion criteria: Mucositis grade 3 and 4 History of chemotherapy and radiation therapy in mouth or pharynx in recent six months Pregnancy use of artificial saliva use of mouthwashes Candidiasis Having oral herpes alcohol consumption smoking Consumption of drugs affecting salivary glands such as antidepressants, opioids, anti-hypertensives, antihistamines Diuretic use Suffering from diseases of the weakened immune system Dehydration-causing diseases such as chronic diarrhea Diseases that cause recurrent oral plague History of connective tissue diseases such as Sogrene, rheumatoid arthritis, lupus liver and kidney disease major depression diseases involving salivary glands such as diabetes

Design outcomes

Primary

MeasureTime frame
Mucositis Mucositis. Timepoint: At the baseline, Weeks 1,2,3,4,5,6,7. Method of measurement: Examination of oral cavity.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Ghazaleh Heydarirad

Shahid Beheshti University of Medical Sciences

ghazalrad@yahoo.com+98 21 8877 6027

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026